Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673
- Malcolm A. Smith
- , Oliver A. Hampton
- , C. Patrick Reynolds
- , Min H. Kang
- , John M. Maris
- , Richard Gorlick
- , E. Anders Kolb
- , Richard Lock
- , Hernan Carol
- , Stephen T. Keir
- , Jianrong Wu
- , Raushan T. Kurmasheva
- , David A. Wheeler
- , Peter J. Houghton
Research output: Contribution to journal › Article › peer-review
75
Scopus
citations